Regarding government funding for supporting the development of technology innovation enterprises, a congressional hearing was held on the topic “The Innovation Pipeline: From Universities to Small Businesses”. Sharklet, as the only technology innovation enterprise representative, was invited to attend alongside three universities.
Since its founding in 2007, Sharklet has received over ten million dollars in various government research grants, which have effectively supported the basic research and product development of this cutting-edge technology.
Among these government research grants, the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program has supported the validation and development of several Sharklet medical products, including catheters, endotracheal tubes, percutaneous gastrostomy tubes, advanced wound dressings, and intraocular lenses. This has provided a solid research foundation for the application of Sharklet technology in the medical field. NIH’s evaluation of Sharklet technology for medical applications is that Sharklet’s technology is significantly improving patient health outcomes and ensuring safety while reducing healthcare costs.
As one of the world’s largest biomedical research institutions, the NIH advances medical science through funding basic and clinical research, known for its outstanding scientific research and innovative capabilities. Receiving long-term research grants from the NIH not only affirms the innovation and medical application value of Sharklet’s technology but also drives the development of multiple innovative medical products by Sharklet.
At this hearing, we introduced to the congressmen the broad applications of Sharklet technology in medical supplies and its innovative role in safeguarding human health. Government funding is crucial for the growth of tech innovation enterprises. NIH’s funding of small tech enterprises for technology development has greatly promoted the medical application of scientific advancements, becoming a vital channel for the U.S. government to drive the growth of medical tech innovation enterprises. Sharklet, with its advanced physical antimicrobial technology, has gained high recognition in the industry. Through government funding, the commercial transformation of Sharklet’s scientific achievements has accelerated, providing critical support for the company’s growth.
Watch the full speech video:
